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early 108 million (45%) American adults have a diagnosis of
hypertension, yet only 1 in 4 patients (24%) has controlled
blood pressure (BP).1 African American patients have the
highest rate of hypertension (56%) among all racial groups and
higher mortality rates from hypertension-induced cardiovascular
diseases.1,2 African American patients may also encounter additional
barriers to managing hypertension, such as less access to health
care and a lack of routine care with a primary care physician (PCP).3,4
Therefore, new strategies and interventions to improve BP control
are still needed.3
Community-based trials have shown success in reaching
traditionally challenging and high-risk populations.3 The Los
Angeles Barbershop Blood Pressure (LABBP) study found that
when 52 community barbershops promoted hypertension care and
referred older, African American male patrons to a pharmacist-led
hypertension management program, systolic BP was reduced.5 Other
team-based care studies with a pharmacist demonstrated improved
BP control as well.6-8 Technology strategies such as telemedicine and
mobile health have improved health outcomes through the use of
BP telemonitoring and smartphone-based medical applications.3,9
Although the strategies seem promising, there are still limitations.
First, the LABBP clinical trial focused on the community setting only
and was not conducted within a large health care system.5 Other teambased care studies largely lack representation of African American
patients, which is especially concerning due to the higher prevalence
of hypertension and poor outcomes in this population.1,2,10 Although
the technology interventions have led to potential improvements
in self-management of hypertension, they may not be applicable to
patients who do not use smartphones or seek routine care with their
PCP.9 More team-based interventions that efficiently address health
care disparities and achieve clinically significant improvements in
hypertension identification and outcomes are needed.3
The purpose of this study was to evaluate the impact of a
pharmacist-led hypertension management program utilizing a
novel technological approach for identifying and engaging patients
with uncontrolled hypertension in a large, vertically integrated
urban health system.
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ABSTRACT
OBJECTIVES: To evaluate the impact of the chronic
medication optimization pharmacist (CMOP) program on
blood pressure (BP) control and time to goal compared with
usual care in the ambulatory care setting.
STUDY DESIGN: This was a retrospective cohort study
that included patients from June 2018 to June 2020
who were seen in an ambulatory care clinic for
hypertension management.
METHODS: Patients aged 18 to 80 years were divided into
2 cohorts based on hypertension management by usual
care or the CMOP program. Patients were enrolled in the
CMOP program either by referral or identification via a data
analytics tool. The primary outcome assessed the proportion
of patients within BP goal (< 140/90 mm Hg) at 3 months.
Secondary outcomes assessed the proportion of patients
within goal at 6 months, time and number of visits to goal,
and adherence (CMOP cohort only).
RESULTS: The primary end point demonstrated a greater
proportion of patients within goal in the CMOP cohort
compared with usual care (69.4% vs 42.3%; P < .001).
The CMOP cohort also displayed a greater proportion of
patients achieving goal within 6 months (75.7% vs 60.4%;
P = .014) and faster time to goal (42.99 vs 63.12 days; P = .002),
but more visits (1.67 vs 1.18; P = .001). Lastly, adherence
improved from 50.4% to 72.1% in the patients with a
documented adherence assessment in the pharmacist group
(P = .03).
CONCLUSIONS: The pharmacist intervention improved BP
control in a primarily African American patient population
compared with usual care. Future studies should assess the
sustainability of this intervention.
Am J Manag Care. 2022;28(4):e121-e125. doi:10.37765/ajmc.2022.88864
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agreement (CPA). The CPA allows pharmacists to
add, discontinue, and/or adjust any medications
for the management of hypertension as well
Strategies to identify high-risk patients are needed for improved hypertension management.
as of other chronic disease states, including
We studied the impact of a pharmacist intervention on blood pressure control, assessing time
to goal and the proportion of patients at goal within 3 and 6 months compared with usual care.
diabetes and hyperlipidemia. The CPA does not
› Suboptimal blood pressure control remains a widespread problem among American adults,
restrict the pharmacist to specific medications
especially in African American populations.
or algorithms; rather, pharmacists follow the
› Team-based interventions that efficiently address health care disparities and achieve
most recent guideline recommendations. All
clinically significant improvements in hypertension identification and outcomes are needed.
interventions are communicated with the
› Pharmacist intervention utilizing a data analytics tool may be an effective strategy for
improving blood pressure control and outcomes.
provider after the pharmacist encounter.
In June 2019, the CMOP program began
managing patients for hypertension via 1 of
2 ways: (1) identifying patients by proactively
FIGURE. Clinical Embedded Pharmacist Workflow
using a data analytics tool composed of an
electronic report linked to the electronic health
record (EHR) or (2) through referrals from
Patients with BP > 140/90 mm Hg
other health care providers. This electronic
tool generates a report of patients who have a
PCP in the health system’s primary care clinics,
Identify patients via data
Patients referred for
analytics tool
medication optimization by PCP
who are on the Epic hypertension registry, and
who had a systolic BP (SBP) of at least 140 mm
Hg and/or diastolic BP (DBP) of at least 90 mm
PharmD calls patient for
PharmD calls patient for
Hg measured at the last ambulatory visit.
enrollment in CMOP
enrollment in CMOP
Pharmacists are able to filter these patients
down to either the clinic or provider level,
and the tool was created in collaboration with
Baseline CMOP visit
a pharmacy analyst. The pharmacists review
• Measure BP
this report as time permits for their respective
• Evaluate adherence
clinics, then reach out via telephone to the
• Optimize current regimen
patient. The workflow is outlined in the Figure.
• Counsel on adherence and lifestyle changes
The initial visit with the pharmacist includes
measuring a baseline BP, evaluating medication
Return for BP check in 2-4 weeks
adherence, optimizing the current medication
regimen via adjusting doses or adding on new
Follow-up CMOP visit
medications, and, lastly, counseling on diet
• Measure BP
and lifestyle changes. Follow-up is scheduled
• Evaluate adherence
2 to 4 weeks thereafter. Initial visits with
• Optimize current regimen
• Counsel on adherence and lifestyle changes
the pharmacist were 60 minutes, whereas
• Return in 2-4 weeks if still uncontrolled
follow-up visits were 30 minutes. If patients
monitored their BP at home, it was reviewed
at the visit, but very few patients had access
BP, blood pressure; CMOP, chronic medication optimization pharmacist; PCP, primary care physician.
to their own monitor. Those patients with
identified medication nonadherence received
counseling and were offered a variety of adherence tools including
pillboxes, enrollment in medication delivery services, or switching
Study Design
to combination therapy as appropriate for the individual patient’s
This was a retrospective cohort study approved by our organization’s
situation. Once patients achieved their BP goal, they were disenrolled
institutional review board. Within this Midwest health system
from the pharmacist program.
there are 30 primary care clinic sites, and 6 of these sites have an
Study Population
embedded clinical pharmacist as part of the chronic medication
optimization pharmacist (CMOP) program. This program was To be eligible for the study, patients had to be aged 18 to 80 years
established in 2016 and operates under a collaborative practice
with an elevated BP, defined as SBP of at least 140 mm Hg and/or
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DBP of at least 90 mm Hg. Patients were required to have 2 or more
BP measurements at the study clinic locations and were stratified
according to clinic location. Exclusion criteria included a diagnosis
of end-stage renal disease, pregnancy, advanced dementia, or
terminal illness. Patients were included only once in the study and
were excluded if they had measurements in both cohorts. Patients
included in the interventional CMOP cohort were managed between
June 2, 2019, and June 1, 2020. Patients in the usual care cohort
were managed by their PCP between June 1, 2018, and June 1, 2019,
and served as the comparison control group. The usual care cohort
was identified by running a report of patients seen by their PCP for
hypertension. The first 111 patients who met inclusion criteria were
included in the comparison group.

Data Collection, Outcomes, and Analyses
Data were extracted from the EHR (Epic). Demographic and baseline
data were collected at the initial visit with the CMOP if in the CMOP
cohort or with the PCP if in the usual care cohort. At each follow-up
visit, BP measurements, number and classes of antihypertensive
agents used, and types of medication changes (defined as the
addition of a new BP medication, increase or decrease in the dose
of an existing BP medication, and switching to a medication within
the same or different class) were collected.
The primary outcome was the proportion of patients at the BP
goal (< 140/90 mm Hg) within 3 months compared with usual care.
Secondary outcomes included the proportion of patients at BP
goal within 6 months and time and number of visits with CMOP
or PCP to BP goal. Medication adherence data were described in
the intervention group only and nonadherence was identified by
patient report during an interview by the pharmacist.
All statistical analyses were conducted with IBM SPSS. To
achieve 80% power and an α of 0.05, the calculated sample size
was 136 patients per cohort. This calculation was based on an
expected difference in BP control of 11% between groups and an
assumed baseline rate of control of 64%. Categorical variables were
compared via χ2 test whereas continuous variables were assessed
via the nonparametric Wilcoxon Mann-Whitney test. Adherence
was assessed in the pharmacist group only using a McNemar
test. Descriptive statistics were used to characterize the baseline
demographics and adherence data.

RESULTS
A total of 794 patients were screened. Overall, 222 patients were
included, with 111 patients in each cohort, all of whom had followup through 6 months. Reasons for exclusion were similar between
each cohort, with the most common reasons being initial BP less
than 140/90 mm Hg, less than 2 BP measurements in 6 months, or
elevated BP not measured at the study clinic (usual care cohort only).
Baseline and demographic information is presented in Table 1.
The median age and race were similar between each cohort, and
both cohorts included a predominantly African American patient
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TABLE 1. Baseline Demographic Information
Variable, n (%)
Age in years, median (IQR)
Male sex, n (%)

CMOP
(n = 111)

Usual care
(n = 111)

P

59 (29-80)

60 (32-79)

.309

60 (54.1)

35 (31.5)

<.001

BMI, mg/kg , mean (SD)

35.6 (11.58)

33.9 (8.97)

.205

Height in inches, mean (SD)

66.7 (4.33)

65.3 (4.45)

.022

Weight in kg, mean (SD)

97.2 (23.93)

94.3 (25.26)

.146

2

Ethnicity, n (%)
African American

109 (98.2)

106 (95.5)

.25

Hispanic

1 (0.9)

1 (0.9)

>.999

Caucasian

1 (0.9)

4 (3.6)

.18

Diabetes

96 (73.8)

41 (67.9)

<.001

Glycated hemoglobin A1c,
%, mean (SD)

8.3 (2.1)

6.6 (1.5)

<.001

7 (5.4)

2 (3.6)

.089

Comorbidities, n (%)

CAD
History of stroke/TIA

14 (11.5)

4 (7.1)

.014

Systolic heart failure

4 (3.1)

1 (1.8)

.096

Diastolic heart failure

0 (0.0)

2 (3.6)

.155

Former smoker

32 (28.8)

27 (24.3)

.447

Current smoker

20 (18.0)

24 (21.6)

.501

Never smoker

59 (53.2)

60 (54.1)

.893

Commercial

53 (47.7)

49 (44.1)

.59

No insurance

1 (0.9)

1 (0.9)

>.999

57 (51.4)

67 (60.5)

.45

ACE inhibitor or ARB

38 (34.2)

43 (38.7)

.486

CCB

61 (55.0)

55 (49.5)

.502

β-Blocker

29 (26.1)

31 (27.9)

.762

Diuretic

46 (41.4)

48 (43.2)

.786

Smoking status, n (%)

Insurance status, n (%)

Government issued
Baseline medications, n (%)

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker;
BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel
blocker; CMOP, chronic medication optimization pharmacist; TIA, transient
ischemic attack.

population. More patients had diabetes and a history of stroke/
transient ischemic attack in the CMOP cohort. Within the CMOP
cohort, there were 31 patients identified by the pharmacist using the
electronic tool and 80 patients who were referred by other health
care providers. All patients within the CMOP cohort were agreeable
to the services provided by the pharmacist.
The primary end point and secondary end points are listed in
Table 2. Within 3 months, 69.4% of patients in the CMOP group
and 42.3% of patients in the usual care group had achieved goal
BP (P < .001). Of the patients who achieved the goal BP, the CMOP
patients achieved it more quickly. The magnitude of the effect was
similar between patients who were referred to the pharmacist and
those who were identified proactively by the pharmacist.
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DISCUSSION

TABLE 2. Primary and Secondary End Points
Primary end point

Proportion of patients at BP goal
within 3 months, n (%)

CMOP
(n = 111)

Usual care
(n = 111)

P

77 (69.4)

47 (42.3)

<.001

Secondary end points
CMOP
(n = 111)

Usual care
(n = 111)

P

Time to goal in days, mean (SD)

42.99 (38.4)

63.12 (46.2)

.002

Number of visits, mean (SD)

1.67 (1.10)

1.18 (0.39)

<.001

84 (75.7)

67 (60.3)

.014

Patients at BP goal within
6 months, n (%)

CMOP (n = 111)

Adherence, n (%)

Baseline

3 months

P

56 (50.4)

80 (72.1)

.03

BP, blood pressure; CMOP, chronic medication optimization pharmacist.

TABLE 3. Antihypertensive Medication Changes
CMOP
(n = 111)

Usual care
(n = 111)

P

No. of BP medications at baseline,
mean (SD)

1.79 (1.15)

1.63 (1.06)

.34

No. of BP medications at 3 months,
mean (SD)

2.15 (1.07)

1.76 (1.03)

.01

New antihypertensive added, n (%)

33 (29.7)

18 (16.2)

.017

3 (2.7)

2 (1.8)

.651

Dose increase, n (%)

32 (28.8)

8 (7.2)

<.001

Dose decrease, n (%)

1 (0.90)

0 (0)

.316

Switched antihypertensive within
same class, n (%)

5 (4.5)

7 (6.3)

.55

Switched to different
antihypertensive class, n (%)

6 (5.4)

6 (5.4)

.99

34 (30.6)

77 (69.4)

<.001

Medications removed, n (%)

No changes, n (%)

BP, blood pressure; CMOP, chronic medication optimization pharmacist.

The antihypertensive medication changes are listed in Table 3.
There was a greater mean number of medications at 3 months in
the CMOP group compared with usual care (2.15 vs 1.76; P = .01).
The classes of medications were generally similar at baseline
and 3 months. The CMOP group more frequently added a new
antihypertensive agent or increased the dosage of an existing agent
compared with usual care.
Lastly, adherence improved from 50.4% to 72.1% in patients with
a documented adherence assessment in the CMOP group (P = .03).
All patients received adherence education (n = 111) and were offered
adherence tools including pillboxes/pill packs (n = 3), enrollment
in medication delivery services (n = 2), switching to combination
medications (n = 2), and switching medications due to cost or
adverse effects (n = 5).
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This study of a pharmacist-led hypertension intervention strategy
enabled by an EHR-based tool demonstrated a 49% relative improvement in BP control compared with usual care. A greater proportion
of patients met the BP goal at both 3 and 6 months. The CMOP
cohort also achieved this goal within approximately 6 weeks
compared with approximately 9 weeks in the usual care group.
Although our predefined sample size was not met, a statistically
significant improvement was nonetheless observed, because the
magnitude of the effect size was greater than expected. The effect of
this intervention is likely attributable to medication adjustments,
adherence education, and efficient identification of patients with
uncontrolled hypertension through the data analytics tool.
The overall findings of this study are consistent with the literature
on pharmacist-led interventions on BP.5-8 In a recently published
systematic review comparing randomized controlled trials of
pharmacist-led interventions, 82% (n = 29) of studies demonstrated
a statistically and clinically significant improvement in BP control,
and nearly 25% showed a statistically significant improvement in
medication adherence.8 Although our study did not assess clinical
outcomes, the time to goal was significantly faster compared with
usual care. Several trials have supported the concept that prompt
BP control produces long-lasting BP reduction and decreases the
incidence of cardiovascular events.11 Furthermore, the types of
medication changes conducted at baseline are consistent with the
literature, as pharmacists are well equipped to intensify current
therapy and utilize guideline-recommended agents.12,13
Other studies have reported the beneficial impact of either an
EHR-based registry approach or a pharmacist-led approach to
improving BP control within a primary care clinic population.14,15
For example, Kaiser Permanente applied systemic implementation
strategies to improve BP management that focused on a variety of
systematic changes, including creating an EHR-based hypertension
registry; however, pharmacists were a small part of this intervention.14
Another study, conducted in the US Department of Veterans Affairs,
reported very similar improvements in BP control associated with
referral of patients with hypertension to a program led by clinical
pharmacists, as we observed in our study.15 Although these studies
contained the key elements of our study—an EHR-based approach
to identifying patients with hypertension and a pharmacist-led
service targeting BP control—our study is unique in that we have
combined these elements into 1 intervention and demonstrated
improved results.

Limitations
Limitations of this study include a selection bias in the CMOP cohort.
Nearly 3 of 4 (72%) patients were referred for medication optimization
for hypertension and/or other comorbidities such as diabetes. However,
no matter the reason for referral, the pharmacist still addressed
hypertension when it was uncontrolled. The BP of referred patients
may inherently be more challenging to bring under control, as the PCP
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has likely already utilized standard approaches to achieve BP goals.
Thus, the impact of the program may be multifactorial. If referrals had
been for hypertension alone, there may have been different outcomes
compared with usual care. Despite this, pharmacists were still able to
improve BP control. Another limitation is that our study population
did not reach the predetermined sample size due to the COVID-19
pandemic, preventing clinical face-to-face encounters between
pharmacists and patients. In fact, half of patients not reaching BP
goals had their initial BP visit conducted in the beginning of 2020 and
would have returned for a BP encounter had the pandemic not led
to the closure of face-to-face encounters in the clinics. Additionally,
the pharmacist adherence assessment is based on patient-reported
number of missed doses per week rather than objective data (ie,
prescription fill history). Also, the usual care group did not have
adherence vs nonadherence documented, so comparisons could not
be made between the 2 groups with regard to adherence improvement.
Although it is best practice to verify subjective data with objective
measures, this may be time consuming and not always possible.
The approach of our pharmacist-led clinic to educate patients and
modify their behaviors appears to be an effective strategy given the
increased rate of patient-reported adherence, coupled with greater
achievement of BP goals. Lastly, we did not compare adverse events
related to hypertension or adverse effects of medications between
the usual care and CMOP cohorts.

CONCLUSIONS
This study demonstrated the success of utilizing pharmacists in the
primary care setting, equipped with an EHR-based electronic tool,
to manage patients with uncontrolled hypertension and achieve
a higher rate of BP control compared with usual care. Additional
studies are needed to assess the sustainability of our proactive
identification strategy on long-term BP control. n
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